Association between JAK2V617F mutation and thrombotic complication in patients with classical Ph-negative chronic myeloproliferative diseases
https://doi.org/10.25789/YMJ.2020.69.04
Abstract
The study was conducted with aim to assess the effect of clinical and laboratory parameters and JAK2V617F mutation on the incidence of thrombotic complications in patients with classical Ph-negative chronic myeloproliferative diseases. JAK2V617F mutation was detected in patients with polycythemia vera, essential thrombocythemia and patients with primary myelofibrosis. Thrombotic complications were significantly more often observed in carriers of the JAK2V617F mutation and in patients with cardiovascular risk factors.
About the Authors
T. N. Aleksandrova
Yakut Science Centre of complex medical problems; National Centre of Medicine
Russian Federation
Russian Federation
ALEKSANDROVA Tuiara Nikonovna – junior researcher of the laboratory of heritable pathology Yakut Science Centre of complex medical problems, hematologist of National Centre of Medicine
I. I. Mulina
National centre of Medicine
Russian Federation
Russian Federation
MULINA Inna Ivanovna – Head of the Department of hematology
K. A. Kurtanov
Yakut Science Centre of complex medical problems
Russian Federation
Russian Federation
KURTANOV Khariton Alekseevich – Candidate of medical sciences, chief researcher – Head of department of molecular genetics
I. E. Solovieva
National centre of Medicine
Russian Federation
Russian Federation
SOLOVIEVA Irina Eremeevna – hematologist
L. D. Terekhova
National centre of Medicine
Russian Federation
Russian Federation
N. I. Pavlova
Yakut Science Centre of complex medical problems
Russian Federation
Russian Federation
PAVLOVA Nadezhda Ivanovna – Candidate of Biological Sciences, leading researcher, Head of hereditary pathology laboratory
V. N. Yadrikinskaya
North-Eastern Federal University
Russian Federation
Russian Federation
YADRIKHINSKAYA Vera Nikolaevna – candidate of medical sciences, associate professor of department «Hospital therapy, professional diseases, clinical pharmacology» Medical Institute
N. A. Solovieva
Yakut Science Centre of complex medical problems
Russian Federation
Russian Federation
SOLOVIEVA Natalya Alekseevna – researcher of the Laboratory of Population Genetics
A. T. Dyakonova
Yakut Science Centre of complex medical problems
Russian Federation
Russian Federation
DYAKONOVA Aleksandra Timofeevna – junior researcher of the laboratory of heritable pathology
References
1. Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease / A.L. Melikyan, IN Subortseva, AB Sudarikov [et al] // Therapeutic archive. – 2017. – T.89, №7. – P.4-9. DOI: 10.17116/terarkh20178974-9
2. Melikyan A.L. Myeloproliferative neoplasia: new data / A.L. Melikyan, I.N. Subortseva // Clinical oncohematology. – 2016.– Vol.9, №2. – P. 218-228.
3. All we know about polycythemia vera: literature review and own experience / K.M. Abdulkadyrov, V.A. Shuvaev, I.S. Martynkevich // Oncohematology. – 2015. – Vol.10, №3. – P.28-42. DOI: 10.17650/1818-8346-2015-10-3-28-42.
4. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [published correction appears in Lancet / EJ Baxter, LM Scott, PJ Campbell // Lancet. – 2005. – Vol.9464, №365. – Р.1054–1061. DOI:10.1016/S0140-6736(05)71142-9
5. Arachchillage DR. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms / DR Arachchillage, M Laffan // Semin Thromb Hemost. 2019. Vol. 45, №6. – Р.604–611. DOI:10.1055/s-0039-1693477
6. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms / B Duangnapasatit, E Rattarittamrong, T Rattanathammethee // Asian Pac J Cancer Prev. – 2015. – Vol.16, №12. P. 5013-5018. DOI: 10.7314/apjcp.2015.16.12.5013
7. Martin K. Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis / K Martin // Curr Hematol Malig Rep. – 2017. – Vol. 12, №5. – Р.389-396. DOI: 10.1007/s11899-017-0400-3.
8. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial / M Griesshammer, G Saydam, F Palandri [et al] // Annals of Hematology. – 2018. Vol.97. – P.1591–1600. DOI: 10.1007/s00277-018-3365-y
9. Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms / S Ball, KZ Thein, A Maiti [et al] // J Thromb Thrombolysis. – 2018. – T.45, №4. – Р.516–528. DOI:10.1007/s11239-018-1623-4
10. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management / A. Casini, P. Fontana, TP. Lecompte // J Thromb Haemost. – 2013. – Vol.11, №7. – P.1215-1227. DOI: 10.1111/jth.12265
Review
For citations:
Aleksandrova T.N., Mulina I.I., Kurtanov K.A., Solovieva I.E., Terekhova L.D., Pavlova N.I., Yadrikinskaya V.N., Solovieva N.A., Dyakonova A.T. Association between JAK2V617F mutation and thrombotic complication in patients with classical Ph-negative chronic myeloproliferative diseases. Yakut Medical Journal. 2020;(1):21-23. https://doi.org/10.25789/YMJ.2020.69.04
Views:
24
JATS XML
Email this article 